GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human cdc-like kinase 3 isoform in complex with leucettine L41

Analyse Crystal structure of human cdc-like kinase 3 isoform in complex with leucettine… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3RAW
Type
protein
Length
700 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dual specificity protein kinase CLK3
EC
2.7.12.1
UniProt
P49761
Ligands
3RA
Pockets
4 · best druggability 0.70

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADual specificity protein kinase CLK3 (EC 2.7.12.1)protein35138% helix, 20% strandP49761
BDual specificity protein kinase CLK3 (EC 2.7.12.1)protein34939% helix, 21% strandP49761

Ligands and binding sites

  • 3RA · 5-(1,3-benzodioxol-5-ylmethyl)-2-(phenylamino)-4H-imidazol-4-one · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13900.700.82463RA
23790.690.81473RA
33110.600.7836empty
41890.570.8035empty

Interfaces

1 interface between chains.

  • A–B · 866 Ų buried · 16 hydrogen bonds · protein-protein

Compared structures

  • 3RAW · Crystal Structure of human CDC-like kinase 3 isoform in complex with leucettine L41 · the same entry in another collection · chain A against A, TM-score 1.00
  • P49761 · AlphaFold monomer V2.0 prediction for dual specificity protein kinase CLK3 (P49761) · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.